124 related articles for article (PubMed ID: 23582466)
1. Ultrasound-integrated tight control in early psoriatic arthritis during adalimumab treatment.
Bandinelli F; Bonacci E; Matucci-Cerinic M
Clin Exp Rheumatol; 2013; 31(3):440-2. PubMed ID: 23582466
[TBL] [Abstract][Full Text] [Related]
2. Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging.
Anandarajah AP; Ory P; Salonen D; Feng C; Wong RL; Ritchlin CT
Ann Rheum Dis; 2010 Jan; 69(1):206-9. PubMed ID: 19204015
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
4. Development of a preliminary US power Doppler composite score for monitoring treatment in PsA.
Gutierrez M; Di Geso L; Salaffi F; Bertolazzi C; Tardella M; Filosa G; Filippucci E; Grassi W
Rheumatology (Oxford); 2012 Jul; 51(7):1261-8. PubMed ID: 22378715
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system.
Yanaba K; Sadaoka A; Yonenaga T; Saeki H; Umezawa Y; Tojo S; Ito T; Kikuchi S; Fukuda K; Nakagawa H
J Dermatol; 2015 Dec; 42(12):1153-9. PubMed ID: 26109492
[TBL] [Abstract][Full Text] [Related]
6. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
7. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
Eder L; Thavaneswaran A; Chandran V; Gladman DD
Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
[TBL] [Abstract][Full Text] [Related]
10. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
Mease PJ; Heckaman M; Kary S; Kupper H
J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
[TBL] [Abstract][Full Text] [Related]
11. Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis.
Tsuji S; Higashiyama M; Inaoka M; Tomita T; Yokomi A; Satoh A; Hirano A; Hayashi M; Tsuji M; Kunugiza Y; Hamada M; Yoshikawa H
Mod Rheumatol; 2013 May; 23(3):529-37. PubMed ID: 22752535
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment in psoriatic arthritis: our experience.
Rioda WT; Adorni G
Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
[TBL] [Abstract][Full Text] [Related]
13. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
Borrás-Blasco J; Gracia-Perez A; Nuñez-Cornejo C; Rosique-Robles JD; Mateu-Puchades A; Casterá MD; Rubio-Fabra M
J Clin Pharm Ther; 2008 Jun; 33(3):321-5. PubMed ID: 18452420
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
15. High-field MRI and powerdoppler sonography: supplementary imaging, techniques in assessing disease activity in patients with psoriasis arthritis (PsA) and rheumatoid arthritis (RA) receiving adalimumab.
Hoehle M
Rheumatol Int; 2013 Feb; 33(2):545-6. PubMed ID: 22138673
[No Abstract] [Full Text] [Related]
16. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
17. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.
Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G;
J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493
[TBL] [Abstract][Full Text] [Related]
18. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.
Vogelzang EH; Kneepkens EL; Nurmohamed MT; van Kuijk AW; Rispens T; Wolbink G; Krieckaert CL
Ann Rheum Dis; 2014 Dec; 73(12):2178-82. PubMed ID: 25115447
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
20. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
